Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1619 1626 1627 1653 1743
This examiner grants 68% of resolved cases
Richard Grant Peckham works within Tech Center 1700 and Art Unit 1600. He has managed 135 resolved cases, resulting in an allowance rate of 68.1%. This rate indicates that a majority of the applications he reviews are granted. The median days to allowance for these successful cases is 1194. Additionally, the data shows an interview lift of 35.1%.
This high lift suggests that conducting an interview with the examiner is a very effective strategy for increasing the probability of an allowance. Practitioners should consider this 35.1% lift when deciding whether to engage in direct communication. With 135 resolved cases, the data provides a reliable basis for planning. The 68.1% allowance rate and 1194 days to allowance suggest a steady path to grant for applicants in Art Unit 1600. Strategic use of interviews can further enhance the likelihood of a positive outcome for those seeking to secure intellectual property rights. Proactive engagement appears to be highly beneficial with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18683078 | COMBINATION THERAPY USING VPS34 INHIBITORS | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 18854174 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | Non-Final OA | COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18557775 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF XANTHINE OXIDASE INHIBITOR | Non-Final OA | LG CHEM, LTD. |
| 17920797 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS II | Non-Final OA | BASF SE |
| 18830098 | SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF | Non-Final OA | Washington University |
| 18805625 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18546143 | Small Molecule Inhibitors of PBRM1-BD2 | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18052449 | PRODRUG COPOLYMERS AND POLYMERIC MICELLES THEREOF FOR THE DELIVERY OF SHORT-CHAIN FATTY ACIDS, THE PROMOTION OF GUT HEALTH, AND THE TREATMENT OF IMMUNE AND/OR INFLAMMATORY CONDITIONS AND FOOD ALLERGY | Non-Final OA | The University of Chicago |
| 18294587 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18850038 | MICROWAVE ABSORBER | Non-Final OA | OSAKA UNIVERSITY |
| 18546116 | MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18629894 | LASOFOXIFENE TREATMENT OF BREAST CANCER | Non-Final OA | Duke University |
| 17620855 | IBOGAINE FORMULATIONS | Final Rejection | CAAMTECH, INC. |
| 18836350 | PREPARATION METHOD OF PYRIDAZINONE DERIVATIVE, AND INTERMEDIATE THEREOF | Non-Final OA | XIZANG HAISCO PHARMACEUTICAL CO., LTD. |
| 17335646 | Compositions and Methods for Increasing Insulin Sensitivity | Non-Final OA | Nalpropion Pharmaceuticals LLC |
| 18726889 | COMPOSITIONS AND METHODS FOR TREATING MACULAR EDEMA ASSOCIATED WITH UVEITIS | Non-Final OA | Clearside Biomedical, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy